Clinical trials: Heart Failure with Reduced Ejection Fraction HFrEF
Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
This is an observational study in which data already collected from people with chronic heart failure is studied. Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well…
- Trial name
- ROVER Japan (NCT06697353)
- Testing
- vericiguat (BAY 1021189)
- Where
- Japan
- Volunteers
- 4,936 people
- Sponsor
- Bayer
Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)
BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation
The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy…
- Conditions
- Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft Surgery (CABG), Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BRIDGE (NCT07741396)
- Testing
- CBCR, BRIDGE mHealth intervention
- Volunteers
- 30 people
- Sponsor
- University of Illinois Chicago
Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan
Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)
The goal of this pragmatic clinical trial is to evaluate whether pharmacist-led education, integrated with interactive visualization dashboards, can enhance medication adherence in patients with heart failure who are prescribed…
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan, Medication Adherence
- Trial name
- NCT06900803
- Testing
- interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Heart Failure
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these…
- Trial name
- PROVE-HF (NCT02887183)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 77 sites in United States
- Volunteers
- 794 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction NYHA Class III-IV
Beta 3 Agonist Treatment in Heart Failure-2
Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with moderate to severe chronic heart failure (LVEF<35%, NYHA…
- Trial name
- BEAT-HF II (NCT03926754)
- Testing
- Mirabegron
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Henning Bundgaard
Heart Failure With Reduced Ejection Fraction (HFrEF)
A Trial of CRD-4730 in HFrEF
CRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial.
- Trial name
- CALIBRATE-HF (NCT07750873)
- Testing
- CRD-4730
- Where
- 2 sites in United States
- Volunteers
- 525 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure With Reduced Ejection Fraction, Exercise Training
Effects of Iron Therapy and Exercise Training in Patients With Heart Failure and Iron Deficiency
It is the aim of the study to prove, if intravenous supplementation with ferric carboxymaltose in iron-deficient patients with heart failure with reduced ejection fraction (HFrEF) leads to better exercise training effects…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Exercise Training, Ferric Carboxymaltose
- Trial name
- IronEx (NCT03803111)
- Testing
- Initial exercise training, Initial FCM, Subsequent FCM
- Where
- Germany
- Sponsor
- Herzzentrum Bremen
Heart Failure With Reduced Ejection Fraction
Ketone Pharmacokinetic Study in HFrEF
The purpose of this study is to test whether an over-the-counter ketone ester drink is well tolerated in people with heart failure on, and not on, a heart failure medication class called SGLT2 inhibitors.
- Trial name
- NCT05757193
- Testing
- DeltaG (250 mg/kg), DeltaG (500 mg/kg)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- VICTORIA (NCT02861534)
- Testing
- Vericiguat
- Volunteers
- 5,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure With Reduced Ejection Fraction
Strategy, Efficacy and Safety of Medication Usage in Heart Failure Patients Who Were Intolerable to GDMT
SEMI trial is a single-center, real-world based prospective cohort study. The study enrolled acute heart failure patients admitting to the hospital and intended to accept heart failure therapy.
- Trial name
- SEMI (NCT05799638)
- Testing
- Guideline-Directed Medication Treatment (GDMT)
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Chongqing Medical University
Heart Failure With Reduced Ejection Fraction
Daily Ambulatory Remote Monitoring System For Post-Dischage Management Of ADHF
Background: Despite the advances in pharmacological management of heart failure (HF), the associated mortality and re-hospitalization for HF remain poor.
- Trial name
- DAVID-HF (NCT03072693)
- Testing
- Home-based remote heart failure management, Home-based physiological parameter recording only
- Where
- Hong Kong
- Volunteers
- 876 people
- Sponsor
- The University of Hong Kong
Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction
Lokelma for RAAS Maximisation in CKD & Heart Failure.
Background: CKD in patients with heart failure (HF) is common and associated with poor prognosis. Despite evidence of benefit with Renin-Angiotensin-Aldosterone-System inhibitor (RAASi) agents, they are avoided due to fear of…
- Conditions
- Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction, Hyperkalemia, ACE Inhibitor Induced Hyperkalaemia
- Trial name
- LIFT (NCT05004363)
- Testing
- Lokelma Oral Product
- Where
- United Kingdom
- Volunteers
- 112 people
- Sponsor
- St George's, University of London
Heart Failure
PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.
- Trial name
- PARTHENON (NCT02957409)
- Testing
- sacubitril/valsartan
- Where
- 32 sites in Canada
- Volunteers
- 1,009 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
This study will address whether the additional use of Ferric Derisomaltose on top of standard care will improve exercise capacity and quality of life in patients with acute heart failure and iron deficiency.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Iron Deficiency, Acute Heart Failure
- Trial name
- COREVIVE-HFrEF (NCT05971732)
- Testing
- Ferric derisomaltose
- Where
- China
- Volunteers
- 146 people
- Sponsor
- China-Japan Friendship Hospital
Heart Failure and Reduced Ejection Fraction, Obesity & Overweight
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
The goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide.
- Conditions
- Heart Failure and Reduced Ejection Fraction, Obesity & Overweight, Tirzepatide
- Trial name
- DUAL-HFrEF (NCT07738276)
- Testing
- Tirzepatide
- Volunteers
- 60 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Heart Failure With Reduced Ejection Fraction, HFrEF - Heart Failure With Reduced Ejection Fraction
Intermediate Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy
This prospective observational study aims to evaluate intermediate clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical…
- Trial name
- NCT07845201
- Volunteers
- 250 people
- Sponsor
- Assiut University
Heart Failure With Reduced Ejection Fraction, Endothelial Dysfunction
Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in HFrEF
Heart failure (HF) is the leading cause of hospitalization in the US. Endothelial dysfunction, characterized by the decreased vasodilatory capacity of the vascular endothelium, is rampant in atherosclerotic diseases such as…
- Trial name
- NCT03380156
- Testing
- TVS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
Type 2 diabetes mellitus (T2DM) is a well-recognized independent risk factor for heart failure (HF). Whereas the prevalence of HF in the general population is 1-4%, it reaches approximately 12% in T2DM patients.
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2, Cardiomyopathies
- Trial name
- NCT04304560
- Testing
- Dapagliflozin 10 MG
- Volunteers
- 60 people
- Sponsor
- Damanhour University
Heart Failure
Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Trial name
- EVOLUTION-HF (NCT05465213)
- Where
- 8 sites in Portugal
- Volunteers
- 283 people
- Sponsor
- AstraZeneca
Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)
This is a multi-center, randomized, sponsor open-label, participant- and investigator-blinded, placebo-controlled, single and multiple dose study to investigate the safety and tolerability of XXB750 in HFrEF/HFmrEF.
- Trial name
- NCT05328752
- Testing
- XXB750
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals